• Browse Industries
• Health Care

• FDLI SmartBrief
• News
• Press Releases
• SmartBlogs
• Topics
• FDA
• Generic drugs
• Medical devices
• Nutrition
• Stem Cells
• Vaccines
• Jobs
• View Job Listings
• Post a Job
• Job Listings FAQ's
• Most Clicked Stories
• FDLI News
• FDLI Reader Polls
• Archive
• RSS

• Find/Post Jobs

• Partner With Us

• Advertise

• About SmartBrief

• Reader Polls

Sales rep says he promoted Risperdal for off-label use

A sales representative for Janssen Pharmaceutica testified that he pushed doctors to consider prescribing antipsychotic drug Risperdal for unapproved use in "augmentation therapy." Matthew D. Thompson said in court that the company did not "think about augmentation in the realm of on-label or off-label at that time."

Bloomberg | 10/28

This story published in FDLI SmartBrief on 10/29/2009

Get stories like these delivered daily for FREE:

FDLI SmartBrief Designed specifically for professionals involved in the food and drug industry, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more